| Document |
Document Title |
|
WO/2008/070143A1 |
The present invention encompasses processes (1) for preparing racemic 2-(benzhydrylsulfinyl)acetic acid by combining the (S)- or the (R)-enantiomer with at least one organic solvent and at least one acid promoter, such as perchloric acid...
|
|
WO2006138508B1 |
Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particular...
|
|
WO/2008/044033A1 |
The invention concerns amide compounds of Formula (I) wherein groups R1, R2, R3, Q1, X, R4, R5, R6, and R7 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmace...
|
|
WO/2008/041140A2 |
This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositio...
|
|
WO/2008/037072A1 |
Compounds of formula ( I ) : are found to be selective inhibitors of cathepsin B, and hence useful in treating a variety of pathological conditions.
|
|
WO/2008/039645A1 |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...
|
|
WO/2008/039999A1 |
Disclosed are sulfone compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, c...
|
|
WO/2008/032453A1 |
Disclosed is a commercially advantageous method for producing a hydrazone represented by the formula (4) below. Specifically disclosed is a method for producing a hydrazone according to the following reaction formula.
|
|
WO/2008/027604A2 |
RF-compositions including surfactants, foam stabilizers, monomers, polymers, urethanes, intermediates, metal complexes, phosphate esters as well as telomerization methods are provided.
|
|
WO/2008/024746A1 |
Compounds of Formula (I): in which R1, R2, R7, R8, R9, R10 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
|
|
WO/2008/015139A2 |
There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R1, R2, n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors...
|
|
WO/2008/013791A2 |
Disclosed herein are compounds of formula (I) and formula (II), where R1-R4 are as defined in the claims, which are antagonists of the androgen receptor and androgen receptor mutations associated with clinical failure of.currently prescr...
|
|
WO/2008/009816A2 |
The invention relates to aromatic sulfinates and sulfonyl halides, and to the preparation thereof. The halides and the sulfinates are respectively of formulae Ar-Z- (CF2) n-CFRf-SO2Y (I) and [Ar-Z- (CF2) n-CFRf-SO2] m M wherein Z is a su...
|
|
WO/2008/009814A1 |
The invention relates to a process for preparing aromatic sulphonylimides, to the sulphonylimides obtained, and to the use thereof as salt of an electrolyte. The sulphonylimides correspond to the formula [R-SO2-N-SO2R']rM (I). R' is an A...
|
|
WO/2008/007780A1 |
Disclosed is a pentadienamide derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof or the like. (I) wherein R1 represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic h...
|
|
WO/2007/147771A2 |
Compounds of the formula (I), (II) or (III); or pharmaceutically acceptable salts thereof, wherein m, n, q, Ar, R1, R2, R3, R4 and R5 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods fo...
|
|
WO/2007/147763A1 |
The application relates to compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein: m is, from 0 to 3; q is from 0 to 3; Ar is optionally substituted aryl or optionally substituted heteroaryl; R1 and R7 each ind...
|
|
WO/2007/142417A1 |
The novel C dialdehyde compound which can be efficiently utilized in the synthesis of carotenoid compounds based on the sulfone chemistry, the preparation method of the same, and the expeditious and practical synthetic processes for lyco...
|
|
WO/2007/131680A1 |
Novel benzamidines of the formula (I) and a use thereof as insecticides
|
|
WO/2007/128137A1 |
A monomer of formula (I) may be used to prepare a poly(arylene ether) of formula (II) wherein k is 1 or 2, n is a non-zero number from 0 to 1, j is 0, 1 or 2, Q is O or S, L is a leaving group, Z is F or CI, Z' is F, CI or an organic gro...
|
|
WO/2007/127639A2 |
This invention relates to novel homotopic prodrugs and medicaments and methods for their preparation, testing and use. In one embodiment, the homotopic prodrug has the general formula (I) wherein (II) is a biologically-active moiety comp...
|
|
WO/2007/125952A1 |
Disclosed is a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, or a solvate of any of them. (I) In the formula, R1 represents an optionally substituted lower alkyl group; Y represents -S(O)n- (w...
|
|
WO/2007/117027A1 |
A process for the production of organic oxides, characterized by oxidizing a substrate with a hypohalous acid, a hypohalite, chlorine, bromine, or iodine in the presence of both a catalytic amount of a compound represented by the general...
|
|
WO/2007/118041A1 |
Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein R1, R2, R3, X and Ar have the meanings given in the specification, and the p...
|
|
WO/2007/112844A1 |
The present invention relates to defined crystalline polymorphs of 3-chloro-N2-[(1S)-1-methyl-2-(methylsulfonyl)ethyl]-N1-{2-me
thyl-4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl}
phthalamide of the formula (A), to processes for...
|
|
WO/2007/109175A1 |
The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive t...
|
|
WO/2007/103221A2 |
The invention encompasses processes for preparing intermediates, such as (R)-modafinic acid and its C1-2 alkyl ester, and the conversion of the intermediates into armodafinil. In particular, the invention concerns: (i) a process for the ...
|
|
WO/2007/103996A1 |
The present invention relates generally to novel 2-(aryloxy)acetamides of Formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables W, Y, Z, R7, R8, and R9 are as def...
|
|
WO/2007/103719A2 |
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with express...
|
|
WO/2007/100074A1 |
Disclosed are a novel 1-fluoro-1,1-bis(arylsulfonyl)methane useful for monofluoromethylation, and a production method thereof. Specifically disclosed is a method for producing a fluorobis(arylsulfonyl)methane represented by the formula (...
|
|
WO/2007/099450A2 |
The present invention relates to a process for the preparation of 2-nitro substituted benzoic acids of formula (I), wherein the (O)PSO2R1substituent(s) is in the 3-, 4- and/or 5-position, R1 represents a straight- or branched-chain alkyl...
|
|
WO/2007/098273A2 |
The invention encompasses crystalline forms of armodafinil , processes for preparing the crystalline forms, and pharmaceutical formulation.
|
|
WO/2007/093772A1 |
The present invention relates to a method of making monomers of the formula X=C (H) -Y-S02-CH2-CH (R) -OH which comprises reacting a compound of the formula Q-Y-S02-CH2-CH (R) -OH with a vinyl-containing organometallic reagent comprising...
|
|
WO/2007/093211A1 |
The invention relates to a process for the treatment of an aqueous mixture comprising a dipolar aprotic compound, comprising: a) an adsorption step, in which the aqueous mixture is brought into contact with a porous adsorbent, whereby th...
|
|
WO/2007/083242A1 |
The invention relates to a process for selectively controlling the crystallisation mesotrione [2-(4-methylsulphonyl-2-nitrobenzoyl)cyclohexane-1 ,3-dione] from aqueous solution in which the aqueous mesotrione solution is introduced to a ...
|
|
WO/2007/081261A1 |
The present invention relates to a hydroxy- sulphureous acid, to a method for preparation of the hydroxysulphureous acid and to products based on said hydroxysulphureous acid, to methods for preparation of said products and to use of sai...
|
|
WO2007010387B1 |
Methods and materials for preparing optically active 3,4-disubstituted cyclopentanones are disclosed. The method includes hydrolyzing one or more compounds represented by Formula (13), or removing an ester moiety from a compound represen...
|
|
WO/2007/079010A2 |
The invention relates to carbonate derivatives of fenicol compounds of formulae I and II, wherein the variables are as defined in the claims, having useful properties as antibiotic prodrugs, together with methods of making and using thes...
|
|
WO/2007/074473A1 |
A process for preparation of Bicalutamide of formula (I), comprising oxidation of compound of formula (II), with potassium permanganate in presence of water or a mixture of water and water miscible solvent and isolating Bicalutamide of f...
|
|
WO/2007/071609A1 |
Compounds of formula I wherein X is O or S(=O)n; n is 0,1 or 2; R1 is optionally substituted alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, halocycloalkyl, cycloalkenyl, halocycloalkenyl, phenyl, hetaryl, pheny...
|
|
WO/2007/071582A1 |
Disclosed are merocyanine derivatives of formula (1), wherein R1 and R2 independently from each other are branched C4-C22alkyl; or branched C4-C12 alkenyl; R3 and R4 independently from each other are cyano; COR7, COOR7; CONR7R8; SO2(C6- ...
|
|
WO/2007/069020A2 |
Described herein are N-hydroxyamlde antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical c...
|
|
WO/2007/068894A2 |
The invention relates to substituted diphenylethers, -amines, -sulfides, and -methanes as useful pharmaceutical compounds for treating respiratory- disorders, pharmaceutical compositions containing them, and processes for their preparation.
|
|
WO/2007/070238A2 |
The present invention generally relates to an improved process for preparing modafinil and analogs thereof. The process minimizes impurities and improves the overall yield by oxidizing a modafinil intermediate compound in a reaction mixt...
|
|
WO/2007/063789A1 |
Disclosed are a compound having a strong COMT inhibitory effect and represented by the general formula (I) below, a pharmacologically acceptable salt thereof, a pharmaceutical composition containing either of them, and uses of them. (I) ...
|
|
WO/2007/060839A1 |
A compound given by the formula (I): has an excellent controlling activity against noxious arthropods.
|
|
WO/2007/054668A1 |
The present invention relates to a process for the synthesis of l-substituted-2-fluoro-4- methylsulfonylphenyl compounds.
|
|
WO/2007/054147A1 |
The present invention relates to the synthesis of antibacterial compounds such as Chloramphenicol and its analogues Thiamphenicol and Florfenicol and particularly to a new reaction for the preparation of the intermediate compound aminodi...
|
|
WO/2007/046513A2 |
The present invention relates to a benzoylurea compound represented by formula (I), wherein X and Y represent a fluorine atom or a chlorine atom, R1 represents a lower alkyl group or the like, R2 represents a lower alkyl group, R3 repres...
|
|
WO/2007/045572A1 |
The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, R5 and X are as herein de...
|
